Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Boehringer Ingelheim’

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of biosimilar to Humira

Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.

Bron: World Pharma News Meer lezen »

Roche, Boehringer tout new IPF analyses to boost their rival medications

The idiopathic pulmonary fibrosis market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since the FDA green-lighted the medications in October, 2014. And this week, both drugmakers upped the ante with positive new data for their contenders.

Bron: FiercePharma Meer lezen »

Boehringer Ingelheim calls for "strong and united" Europe

With Brexit looming, Boehringer Ingelheim has issued a plea for EU unity and a warning that the common internal market and free movement of labour “should not be gambled with lightly”. Boehringer’s board member in charge of finance – Simone Menne – took pains to talk up the EU’s achievements, and Boehringer’s contribution to that, […]

Bron: PMLiVE Meer lezen »

Boehringer steps into Humira race with US and EU biosimilar filings

Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted filings to the FDA and EMA for its own biosimilar version of Abbvie’s best-selling drug.  

Bron: InPharm.com Meer lezen »

Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma

Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma.

Bron: World Pharma News Meer lezen »

Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease

German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of the disease.  

Bron: InPharm.com Meer lezen »

Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug

Horizon Pharmaceuticals has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is marketed under the trade names Imukin, Imukine, Immukin and Immukine in an estimated 30 countries across Europe and the Middle East.  

Bron: InPharm.com Meer lezen »

Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials

German drugmaker Boehringer Ingelheim on said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk of lung cancer progression by 27% versus AstraZeneca’s (LSE: AZN) Iressa (Gefitinib).  

Bron: InPharm.com Meer lezen »

AbbVie pays $595m upfront for experimental Boehringer psoriasis drug

AbbVie is betting big on the future of an experimental psoriasis drug, paying $595m upfront for the rights to Boehringer Ingelheim’s BI 655066 candidate – currently in Phase III development for the condition.

Bron: InPharm.com Meer lezen »

Sanofi-Boehringer talks may signal more swaps ahead for ‘merger mania’ in 2016

Is the swap destined to be pharma’s next M&A trend? When dealmakers tot up the advantages of Sanofi and Boehringer Ingelheim’s asset-trade talks–and add them to the big GlaxoSmithKline-Novartis swap-out earlier this year–they might follow up with barter arrangements of their own, M&A experts say.

Bron: FiercePharma Meer lezen »

« Oudere artikelen |